For high-risk patients who have been exposed to COVID-19, monoclonal antibody therapy can reduce the risk of severe disease, hospitalization, and death by 70%, and decreases your odds of infection by over 80%—or if you are infected, reduce the length of COVID-19 symptoms by four days, on average. Early treatment saves lives!